Abstract
Prostate Imaging Reporting and Data System version 2 (PI-RADS v2) identifies prostate cancer on the basis of multiparametric MRI (mpMRI). As an assessment tool, it correctly predicts clinically significant cancer in the vast majority of cases. In this light, we report a rare patient, for whom a PI-RADS 5 lesion vanished over the course of 13 months.
MeSH terms
-
Biopsy, Needle
-
Diffusion Magnetic Resonance Imaging / methods*
-
Follow-Up Studies
-
Humans
-
Immunohistochemistry
-
Male
-
Middle Aged
-
Neoplasm Invasiveness / pathology
-
Neoplasm Staging
-
Prostate-Specific Antigen / blood*
-
Prostatic Neoplasms / blood
-
Prostatic Neoplasms / diagnostic imaging*
-
Prostatic Neoplasms / pathology*
-
Remission, Spontaneous*
-
Risk Assessment
-
Watchful Waiting
Substances
-
Prostate-Specific Antigen